REDO study: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimization.
Phase of Trial: Phase IV
Latest Information Update: 05 Jan 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REDO
- 03 Jan 2017 Status changed from planning to recruiting.
- 30 Nov 2016 New trial record